Immutep Ltd has released a press release.
Immuteps partner EOC pharma to start Ph II trial in MBC
Filed with ASX ·
6ix hasn’t read this filing yet.
In the deck
Story so far
Earlier from Immutep
- Proposed issue of Securities - IMM
- Pause in Trading
- Encouraging Phase II TACTI-002 data reported at SITC 2020
- Immutep Announces Australian Patent Grant for IMP701
- Immutep enters into a Licence & Collaboration with LabCorp
Later from Immutep
- Immutep Upscales Efti Manufacturing
- Immutep granted US patent for eftilagimod alpha with a PD-1
- Recruitment of head & neck cancer patients completed for ph2
- Ulcerative Colitis Phase II Study of GSK2831781 Discontinued
- Phase II study for eftilagimod alpha in COVID-19 advances
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep